Pfizer Inc (PFE)vsViking Holdings Ltd (VIK)
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
VIK
Viking Holdings Ltd
$82.67
-1.55%
CONSUMER CYCLICAL · Cap: $37.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 874% more annual revenue ($63.32B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 11.8%. PFE trades at a lower P/E of 20.2x. VIK earns a higher WallStSmart Score of 66/100 (B-).
PFE
Buy55
out of 100
Grade: C
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Intrinsic value data unavailable for VIK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Every $100 of equity generates 255 in profit
Earnings expanding 226.6% YoY
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
Premium valuation, high expectations priced in
Trading at 33.7x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bull Case : VIK
The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
PFE profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK carries more volatility with a beta of 1.57 — expect wider price swings.
VIK is growing revenue faster at 27.8% — sustainability is the question.
PFE generates stronger free cash flow (2.2B), providing more financial flexibility.
Bottom Line
VIK scores higher overall (66/100 vs 55/100), backed by strong 17.6% margins and 27.8% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?